An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation

Inclusion Criteria6

• Female patients aged ≥ 18 years old;
• Signed ICF, including consent for archival FFPE tumor tissue block testing;
• Newly diagnosed, histologically confirmed, advanced (III-IV stage) EC, with the date of diagnosis of histologically confirmed disease within 4 months before inclusion;
• Endometrioid type G3 or any non-endometrioid histological type of EC (such as serous carcinoma, clear cell carcinoma, mixed carcinoma, undifferentiated and dedifferentiated carcinoma, carcinosarcoma, others);
• The presence of biopsy or postoperative archival FFPE tumor sample (block);
• Availability of source medical documentation.